Molecular docking showed that dasatinib, a small molecule tyrosine kinase inhibitor used in the treatment of chronic lymphocytic and acute lymphoblastic leukemia, could target DGKG. The gene discussed is DGKG; the disease is acute lymphoblastic leukemia.